The study, conducted by a team of health economics researchers led by Nasim Jaberi and Vahid Alipour of Iran University of Medical Sciences together with Jalal Arabloo and Parviz Mohamadzadeh of the University of Tabriz, was published in BMC Health Services Research. The team set out to fill a conspicuous gap: while the broader literature on firm survival is vast, no comprehensive synthesis had focused specifically on pharmaceutical companies, an industry whose economics, regulatory burdens, and innovation cycles differ sharply from those of manufacturing or services. Their goal was to identify the key determinants of pharmaceutical company survival in a form useful to policymakers and decision-makers who shape the environment in which these firms operate.

Methodologically, the review was designed to the highest standards of evidence synthesis. The authors followed the PRISMA 2020 reporting guidelines and prospectively registered the protocol in PROSPERO under registration number CRD42024553565. They searched four major databases, PubMed, Scopus, Web of Science, and ProQuest, without applying any date restriction, and supplemented these searches with additional sources. Crucially, they restricted inclusion to quantitative studies that employed formal survival analysis methods to examine the survival or exit of pharmaceutical companies, whether through mergers, acquisitions, bankruptcy, or other forms of market departure. Data extraction used a standardized form capturing study characteristics, analytical methods, variables, and findings, and because the included studies were statistically and conceptually heterogeneous, the team performed a narrative synthesis rather than a pooled meta-analysis.

The scale of the screening exercise was formidable. The initial search returned 35,129 records, which the authors distilled down to 58 included studies published between 1995 and 2024. More than half of these studies, 58.62 percent, appeared in the last decade, a signal that questions of pharmaceutical firm longevity have grown sharply in academic urgency as the industry consolidates. Geographically, the evidence base was heavily skewed: the vast majority of studies came from high-income countries, with the United States dominating the landscape. This concentration matters, because the determinants of survival in a mature, heavily regulated, capital-rich market may differ substantially from those in emerging pharmaceutical economies, a limitation the authors acknowledge explicitly.

On the technical side, two statistical workhorses dominated the field. The Cox proportional hazards model, which estimates how covariates multiply the instantaneous hazard of exit at any point in time, was the most common analytical method, followed closely by logistic regression, which models the probability of exit over a defined period. The prevalence of Cox models reflects the field’s reliance on time-to-event data, where firms are tracked from entry or a baseline year until they exit, are acquired, or the observation window closes. These methods allow researchers to handle censored observations, firms still alive when the study ends, which is essential in survival research, though the authors note that methodological choices varied considerably across the 58 studies, contributing to the heterogeneity that precluded quantitative pooling.

The heart of the review is its taxonomy of survival determinants. From the 58 studies, the team extracted 63 distinct factors influencing pharmaceutical company survival, which they organized into five categories: firm-specific characteristics, industry-specific conditions, macroeconomic conditions, geographic conditions, and owner or manager characteristics. The firm-specific group proved the richest, encompassing attributes such as company size, age, financial performance, and innovation-related activity. Industry-specific factors centered on market competition, while macroeconomic and geographic categories captured the broader economic and regional environments in which firms operate. The fifth category, owner and manager characteristics, acknowledged that the identities, experience, and decisions of those who run pharmaceutical firms shape their fate in ways that balance sheets alone cannot capture.

Among these 63 factors, five emerged as the most frequently studied: firm size, firm age, market competition, innovation-related activities, and financial performance. Yet the most striking finding is how unsettled the evidence remains. For each of these headline determinants, the review found mixed results regarding their impact on survival. Larger firms, for instance, may benefit from economies of scale, diversified portfolios, and deeper pockets for regulatory compliance, but they can also become acquisition targets or suffer bureaucratic inertia. Younger firms face the liability of newness, yet in an industry where a single blockbuster drug can transform a startup, age is no simple shield. Intense competition can weed out weak players or, alternatively, spur the innovation that keeps strong ones alive. The authors conclude that the impact of many determinants is ambiguous and heavily context-dependent, a sobering verdict for anyone hoping for a simple formula for longevity.

This ambiguity does not render the synthesis useless; rather, it reframes the policy question. Because survival determinants interact with context, the authors argue, policymakers should pursue targeted interventions tailored to firm circumstances rather than blanket measures. Their recommendations, grounded in the patterns across the 58 studies, include financial and regulatory support specifically designed for small pharmaceutical firms, which face disproportionate survival risks; incentives for high-risk research and development, where the social value of innovation exceeds what private actors can justify; streamlined drug approval pathways that reduce the fixed costs of regulation; mentorship programs connecting experienced industry leaders with emerging companies; and workforce development initiatives to secure the specialized human capital the industry requires. Each proposal maps onto one or more of the determinant categories the review identified, translating an academic taxonomy into an actionable agenda.

The review also maps the frontier of ignorance. Firm-specific and industry-specific factors have absorbed most of the scholarly attention, while macroeconomic, geographic, and ownership-related determinants remain comparatively underexplored. The geographic skew of the evidence base compounds the problem: with studies concentrated in the United States and other high-income settings, the survival dynamics of pharmaceutical firms in middle- and low-income countries, where generic manufacturers and emerging biotech sectors are often most vulnerable, are largely invisible in the quantitative record. The authors call explicitly for future research to focus on these understudied regions and on contextual factors, arguing that only a more globally representative evidence base can support the kind of differentiated policy the industry’s heterogeneity demands.

For an industry that underwrites modern medicine, the fragility documented here carries consequences far beyond shareholders. Every merger that folds a research pipeline into a larger acquirer, every bankruptcy that orphans a promising compound, represents a potential loss for patients and public health systems. By systematically cataloguing what three decades of survival analysis have revealed, and just as importantly what they have not, this review provides the first comprehensive map of the terrain on which pharmaceutical companies live and die. Its message is double-edged: the levers of survival are known in outline, size, age, competition, innovation, and finances chief among them, but pulling them effectively requires understanding the context in which each firm operates. In a sector where the stakes are measured in lives as much as in revenue, that nuance is not an academic nicety. It is the difference between policy that strengthens the industry’s resilience and policy that merely reshuffles its wreckage.

Subject of Research: Determinants of survival and exit among pharmaceutical companies

Article Title: Critical survival factors in the pharmaceutical industry: a systematic review of methodologies and determinants from 1995 to 2024

Article References: Critical survival factors in the pharmaceutical industry: a systematic review of methodologies and determinants from 1995 to 2024. (n.d.). https://doi.org/10.1186/s12913-026-15639-z

Image Credits: AI Generated

DOI: 10.1186/s12913-026-15639-z

Keywords: pharmaceutical industry, firm survival, systematic review, survival analysis, Cox proportional hazards model, mergers and acquisitions, innovation, market competition, health economics, R&D investment, pharmaceutical policy, firm size

The report itself is scheduled for release in October 2026, and its scope is unusually broad for this kind of analysis. Rather than simply cataloging list prices at launch, the 2026 edition will examine launch price trends across four full years of FDA approvals, spanning 2022 through 2025. That longitudinal window matters. A single year of launch prices can be distorted by a handful of high-profile gene therapies or cancer treatments; four years of data allow analysts to distinguish genuine market-wide trends from statistical noise, and to see whether the trajectory of introductory prices is rising faster than inflation, faster than the economy as a whole, or in line with the added clinical value that new drugs actually deliver.

The access component is arguably the more novel half of the project. ICER and West Health plan to combine real-world pharmacy and medical claims data with payer coverage policies and direct patient surveys, building a picture of what happens after a drug is approved and priced. List price is only the opening move in a complicated negotiation between manufacturers, insurers, pharmacy benefit managers, and patients. A drug may carry a headline price of hundreds of thousands of dollars a year yet be broadly covered with manageable cost-sharing, or a nominally cheaper medicine may sit behind restrictive prior-authorization requirements, step therapy protocols, or specialty-tier coinsurance that effectively locks patients out. By triangulating claims data, coverage policy documents, and patient-reported experience, the report aims to measure that second, less visible dimension of the market.

ICER published the first edition of the Launch Price and Access Report in 2025, and its findings signaled a significant jump in launch prices that outpaced both inflation and gross domestic product growth. That debut established the methodology the partnership will now extend: tracking the introductory prices of newly approved treatments and comparing them against benchmarks of economic growth and the clinical benefit those treatments provide. The 2025 report’s central finding, that launch prices were climbing well beyond general economic measures, set the stage for the question the 2026 edition will pursue: whether that pattern persisted through 2025, and whether patient access kept pace, deteriorated, or held steady as prices rose.

The institutional logic of the partnership is straightforward. ICER brings the analytical machinery of comparative effectiveness review, a framework it has refined over more than a decade of assessing drugs against clinical evidence and assigning them value-based price benchmarks. West Health brings a policy focus sharpened by years of research on healthcare costs, particularly as they bear on older adults, along with the polling infrastructure of the West Health-Gallup Center on Healthcare in America. Together, the two organizations are positioning the annual report as a recurring, independent yardstick for a market that has historically lacked one. There is no official government publication that systematically tracks launch prices of newly approved drugs against their clinical value; the field has relied on academic analyses and nonprofit reports to fill that gap.

The urgency behind the collaboration is documented in the West Health-Gallup Center’s State of the States 2025 report on healthcare in America. According to that survey, one in five Americans, a record high of 20 percent, said they or someone in their household could not afford prescription medications in the previous three months. Nearly one in three reported skipping a needed medical procedure or test within the past year because of cost. Almost half of adults said they worry they will not be able to afford necessary healthcare services next year. Those figures describe a population for whom the price of a new medicine is not an abstract policy debate but a monthly arithmetic of refills, rent, and groceries.

Leadership at both organizations framed the partnership in terms of that lived reality. Sarah K. Emond, ICER’s president and chief executive officer, said the institute is proud to work with a partner that shares its mission of addressing access and affordability challenges for patients, and that together the organizations will provide an independent analysis of launch price trends over the past four years while assessing patient access to newly launched medicines. Timothy Lash, president and chair of the West Health Policy Center, offered a sharper formulation of the problem. Prescription drugs, he noted, are a key tool for enabling healthy aging, but high prices continue to put needed treatments out of reach for far too many Americans, including older adults. New drugs should improve people’s health, he argued, and the financial reward for developing them should reflect those improvements.

Lash’s comment gestures at the economic theory that underpins ICER’s entire enterprise: the idea that a drug’s price should be proportional to the health it produces. In a well-functioning market, value and price track each other, and the promise of reward drives investment toward the innovations that deliver the greatest benefit. When launch prices detach from measured clinical value, the incentive structure warps. Manufacturers are rewarded for prices that bear little relation to therapeutic advance, payers respond with tighter utilization management, and patients encounter a coverage landscape that grows more labyrinthine each year. Understanding the value of new drugs, as Lash put it, is critical for developing policies that ensure affordable access while also signaling to innovators that the best drugs get the best prices. The annual report is designed to supply exactly that understanding, year after year, in a form that policymakers, payers, and researchers can cite and compare over time.

The methodological stakes are considerable. Claims data reveal what patients actually filled and what they actually paid, capturing the discounts, rebates, and coverage decisions that never appear on a list price. Payer coverage policies reveal the formal architecture of access, including which drugs land on preferred tiers and which require documented failure of cheaper alternatives first. Patient surveys add the dimension neither dataset can supply: whether people delayed filling a prescription, cut pills in half, or abandoned a therapy at the pharmacy counter. No single source tells the whole story, and the report’s triangulation of all three is what distinguishes it from the price-tracking exercises that dominate pharmaceutical market coverage.

For the pharmaceutical industry, the annualized report creates a new layer of public accountability. Launch prices are set in a period of deliberate opacity, before rebate negotiations are visible and before utilization data accumulate, and manufacturers have long defended introductory prices as reflecting anticipated value and development costs. A recurring, independent analysis that publishes those prices alongside measures of patient access will make it harder for the market’s opening moves to escape scrutiny, and easier for legislators, insurers, and patient advocates to argue from evidence rather than anecdote. Whether the 2026 findings show the price trajectory of 2022 through 2025 bending toward value or continuing to outrun it, the report will establish a baseline that future years can be measured against, which is precisely what an annual series is built to do. The complete report timeline is available through ICER’s assessment page, and the findings, when they arrive in October, will land in the middle of an ongoing national argument about what Americans should pay for the newest medicines, and who gets left behind when the answer is too high.

Subject of Research: Annual analysis of launch prices and patient access for newly approved FDA drugs

Article Title: ICER, West Health partner on annual new drug Launch Price and Access Report

Article References: ICER, West Health partner on annual new drug Launch Price and Access Report. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: ICER, West Health, drug pricing, FDA approvals, patient access, prescription drug costs, health policy, launch prices, pharmaceutical industry, healthcare affordability, drug value assessment, Gallup survey

The review, published in the Cochrane Database of Systematic Reviews under the title Pharmaceutical industry information and promotional strategies aimed at prescribers, compiled observational data on prescribers who had received various forms of industry contact, including advertising and education, gifts and payments, and free samples. The technical strength of a Cochrane review lies in its systematic approach: the authors searched, appraised and synthesized studies according to predefined criteria, allowing patterns to emerge across heterogeneous settings rather than relying on any single investigation. What emerged was a coherent signal that exposure to industry promotion changes behavior in measurable ways, shifting prescribing toward promoted products and, in a substantial share of cases, away from prescribing that best serves patients clinically or economically.

Grundy, who also directs the WHO Collaborating Centre for Governance, Accountability, and Transparency in the Pharmaceutical Sector at the University of Toronto and is one of two Canadian authors on the review, emphasizes that these marketing tactics are not confined to any single country or regulatory environment. The same multi-national companies market their drugs worldwide, meaning the dynamics documented in the review likely apply broadly across health systems. In the United States, where the Open Payments system requires companies to publicly report transfers of value to physicians, just over half of all licensed physicians have accepted a payment of some kind, including something as ordinary as a free meal. That figure, Grundy notes, cuts two ways. It shows that companies concentrate their marketing resources on physicians expected to deliver the highest return on investment and to prescribe more of the promoted drug, but it also reveals that a large number of physicians deliberately choose not to interact with pharmaceutical companies at all and remain independent of these influences.

The economics of this influence deserve particular scrutiny. When physicians accept payments or meals, the data show they subsequently prescribe more of the promoted drug, and when that drug is a brand-name product with cost-effective alternatives available, the consequences ripple outward through the health system. Patients face higher co-pays and greater out-of-pocket costs, while payers and public programs absorb inflated drug expenditures that may deliver no additional clinical benefit. In this sense, the review frames industry promotion not merely as an ethical concern about professional independence but as a measurable driver of health system costs and of inequities in what patients pay at the pharmacy counter.

Canada occupies a revealing position in this evidence base. No Canadian studies were included in the review, largely because the country lacks a mechanism to track how much pharmaceutical companies pay physicians and nurse practitioners, or why those payments are made. Unlike the United States, which maintains its public Open Payments database, Canada has no comparable transparency infrastructure at the national level. Grundy points out that surveys and qualitative research outside this review suggest free meals and payments are nonetheless likely common among Canadian prescribers, meaning the absence of Canadian data reflects a gap in transparency rather than an absence of the phenomenon itself. For policymakers, this is a concrete and actionable finding: a country cannot manage or evaluate influences it does not measure.

The review did not stop at documenting the problem. A subset of the included studies examined what happens when institutions adopt conflict-of-interest policies or restrict physician interactions with industry within practice settings such as medical schools and teaching hospitals. The results were encouraging. In environments where such policies were in place, physicians tended to prescribe less overall, or to prescribe more appropriate treatments, suggesting that structural safeguards can meaningfully mitigate the effects of promotional exposure. The review authors argue that more robust conflict-of-interest policies represent an important way forward, shifting the burden of independence from the individual conscience of each clinician to the systems in which care is delivered.

Grundy frames this as a matter of institutional responsibility rather than personal blame. Prescribers, she argues, need independent, evidence-based sources of drug information to maintain their independence in practice and to remain trustworthy and accountable to the people they serve. The studies included in the review demonstrate that practice environments can be deliberately designed to promote and preserve that independence, and that this is best achieved collectively, within health systems and institutions, rather than leaving individual clinicians to resist sophisticated, well-resourced marketing campaigns on their own. This reframing matters, because decades of research on professional behavior suggest that relying solely on individual willpower against systematic commercial pressure is a weak intervention compared with changing the environment itself.

There is also an important scope question raised by the findings. While most of the available research focused on physicians, physicians are no longer the only prescribers in many health systems, including Canada. Descriptive studies using the United States Open Payments data, which were not part of this review, have found that advanced practice nurses, including nurse practitioners and clinical nurse specialists, are also targets of industry promotion. As scope-of-practice expansions place more prescribing authority in the hands of nurses and other non-physician clinicians, the reach of pharmaceutical marketing expands with it. Grundy is explicit on this point: this is not just a problem for medicine, it affects the entire healthcare team, and the goal should be to create healthcare environments that safeguard the independence and integrity of care for every prescriber within them.

For readers weighing the practical implications, the review offers a clear evidence-based agenda. Health professional schools, hospitals, professional societies and health systems can adopt and enforce conflict-of-interest policies that limit promotional contact, particularly during training when prescribing habits are formed. Jurisdictions without transparency mechanisms, Canada among them, can establish mandatory disclosure of industry payments to all prescribers, not only physicians. Clinicians and educators can prioritize independent sources of therapeutic information. And patients, whose co-pays and out-of-pocket costs absorb much of the financial consequence, have a stake in demanding that prescribing decisions rest on clinical evidence rather than commercial relationships. The Cochrane evidence indicates that none of these changes requires a scientific breakthrough, only the institutional will to act on what the data already show.

What makes this review resonate beyond academic circles is its scale and its consistency. With evidence from more than 93 studies and the observed practices of millions of prescribers, the association between industry payments and prescribing behavior is no longer a contested curiosity of health services research; it is a documented, repeatable pattern across health systems and regulatory regimes. The finding that conflict-of-interest policies measurably improve prescribing adds a constructive counterweight, demonstrating that the influence of promotion is neither inevitable nor irreversible. As Grundy and her colleagues make clear, the task now is to translate that evidence into policy, so that the environments in which clinicians train and practice actively protect the independence on which safe, appropriate and affordable prescribing depends.

Subject of Research: The influence of pharmaceutical industry marketing and payments on physician prescribing behavior

Article Title: Study links pharmaceutical industry payments to changes in physicians’ prescribing practices

Article References: Study links pharmaceutical industry payments to changes in physicians’ prescribing practices. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pharmaceutical industry, prescribing practices, Cochrane review, conflict of interest, Open Payments, physician payments, drug marketing, health policy, inappropriate prescribing, healthcare costs, Quinn Grundy, University of Toronto

The quantitative texture of the interviews reinforces the qualitative alarm. When researchers coded the sentiment expressed across all of the conversations, they found that 74 percent of coded sentiment statements were negative. That figure is remarkable for a sector that is frequently celebrated as a pillar of Europe’s future economic strategy, and it suggests that the pessimism is not the grumbling of a vocal minority but a systemic assessment shared across the innovation chain. Crucially, the respondents did not attribute the sector’s difficulties to a single failing. Instead, they identified multiple structural bottlenecks that compound one another at every stage of the journey from laboratory discovery to market-ready product. The report frames these failures through the well-established concept of “valleys of death,” the perilous transitional phases in which promising scientific ideas and young companies routinely perish before reaching commercial viability.

The first valley of death concerns translation: the process of converting scientific discoveries into viable, financeable companies. Here the report offers a genuinely paradoxical picture. German and European biotechnology research is described as world-class, with the underlying science fully capable of anchoring a globally competitive industry. Yet the machinery that should carry that science out of universities and research institutes and into the hands of entrepreneurs is badly malfunctioning. Technology transfer offices, the institutional intermediaries responsible for licensing discoveries and supporting spinout formation, received a positive assessment from only 17 percent of respondents. That overwhelming dissatisfaction points to offices that too often act as bureaucratic gatekeepers rather than enablers, imposing slow procedures, inconsistent licensing terms, and limited commercial expertise on researchers who are attempting to move at the speed that competitive markets demand.

The second valley of death opens when young companies need substantially larger amounts of capital to develop and scale their technologies. It is at this stage that Europe’s disadvantage relative to the United States becomes most visible and most consequential. According to market data cited in the report, European venture capital funds account for only around seven percent of the global life sciences venture capital market, while US funds command 63 percent. That imbalance shapes corporate geography in tangible ways. Several founders interviewed for the report said that US investors made the establishment of a US entity or subsidiary a condition for participating in later financing rounds. Six of the eight founders questioned on this specific issue had already considered moving part of their operations to the United States, a migration of entrepreneurial activity that, once it begins, tends to be self-reinforcing as talent, suppliers, and follow-on capital cluster around the relocated companies.

What gives the report its distinctive tension is the argument that this grim picture coexists with a genuine, but temporary, opportunity. The authors cite market data showing that some areas of early-stage financing in the US biotechnology sector declined by 38 percent between the first quarters of 2025 and 2026. Several of the experts interviewed view this American retrenchment as a window during which Europe could capture deal flow, talent, and momentum that would otherwise flow to Boston, San Francisco, and other established US biotech hubs. The opportunity is conditional, however. It exists only if the necessary reforms are implemented now, while American investors are pulling back. Encouragingly, almost half of those interviewed expressed optimism that Europe can close the gap, suggesting that the pessimism documented in the sentiment analysis reflects frustration with current structures rather than despair about the continent’s underlying potential.

De Véricourt frames the stakes in explicitly strategic terms. “The window is closing rapidly. If we do not act now, we will not only lose individual companies to the United States. We risk permanently losing our ability to build internationally competitive biotech companies from our own research. In the long term, this would also weaken our ability to pursue fundamental research,” he says. The causal chain he describes runs in both directions: strong company formation justifies and funds fundamental research, while the erosion of the commercial pathway eventually starves the scientific base itself. For a continent that has staked much of its economic future on strategic sovereignty in critical technologies, the prospect of a permanently atrophied biotech sector carries implications that extend well beyond the industry’s own balance sheets, touching public health preparedness, industrial resilience, and the attractiveness of European research careers.

Perhaps the report’s most important diagnostic conclusion is what the problem is not. The authors are clear that the issue is not primarily a lack of research, funding programs, or institutions. Europe has scientists, it has grants, and it has agencies. What matters, the report argues, is whether existing resources are deployed in the right form, at the right time, and with a clear focus on successful company formation and growth. “More of the same will not be enough. The underlying structures and incentives must change,” de Véricourt adds. This framing shifts the policy debate away from the familiar demand for larger budgets and toward the harder work of institutional redesign: rewiring incentives so that universities, investors, and public programs are rewarded for producing companies that survive and scale rather than for the volume of patents filed or grants disbursed.

On the financing and scaling side, the report’s priorities include mobilizing institutional capital from pension funds, insurers, and other pools of long-term capital that currently sit largely on the sidelines of European venture investing. It also calls for more reliable tax incentives for private venture capital, giving individual investors and funds a predictable framework for backing risky early-stage science. A third proposal would establish a pan-European biotech listing segment, a dedicated public-market venue that would allow European companies to secure later-stage growth financing and complete initial public offerings on European exchanges. The strategic logic is direct: today, a European biotech that needs serious scale-up capital typically faces a choice between being acquired by a large pharmaceutical company or listing in the United States, and either outcome exports the value created by European science. A functioning European listing venue would keep that value, and the companies that generate it, inside the European economy.

The recommendations for the earliest stages of company formation are equally concrete. The report proposes opening public funding programs to companies that do not originate from universities, acknowledging that valuable biotech ventures can emerge from paths other than academic spinouts. It urges faster access to initial financing for founders, faster company formation through digital procedures, and fewer notarial and administrative hurdles, the accumulated friction that can add weeks or months to the incorporation of a startup in parts of Europe. Interviewees further emphasize the need to connect founders more systematically with investors, experienced entrepreneurs, and the pharmaceutical industry, building the relational infrastructure that in the United States has historically compensated for formal gaps in the system. On the translation side, the report recommends independent, professionally run translation institutes to complement existing university technology transfer structures, supporting research teams early with validation, team building, and financing. Technology transfer offices themselves should evolve from gatekeepers into facilitators, adopting standardized licensing terms, faster procedures, and stronger commercial expertise. The report builds on a 2025 predecessor, “Assessing Deep-Tech Innovation Hubs in Germany: The Case of Biotechnology,” which assessed Germany’s biotech innovation performance through a comprehensive index, and together the two documents sketch both the scale of the problem and a detailed roadmap for solving it before the window closes.

Subject of Research: Structural barriers to biotechnology innovation and company formation in Germany and Europe

Article Title: Concern over European biotech: the window for change is narrow – and closing fast

Article References: Concern over European biotech: the window for change is narrow – and closing fast. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: biotechnology, Europe, venture capital, technology transfer, startups, ESMT Berlin, valleys of death, strategic sovereignty, innovation policy, Germany, pharmaceutical industry, reform proposals

The fiscal backdrop gives the findings particular urgency. The FY2027 President’s Budget Request proposed cutting the National Institutes of Health by 12 percent, roughly $5 billion, and reducing the National Science Foundation by more than half, alongside a 15 percent cap on NIH indirect cost rates, a figure far below the 50 to 60 percent rates most research universities negotiate. With final FY2027 appropriations deferred until after the midterm elections, science agencies are operating on a stopgap basis, leaving institutions uncertain about their federal funding outlook. Against that uncertainty, the Cure analysis offers a data-driven map of how universities can diversify, and it arrives with a genuinely surprising conclusion: there is no single blueprint for successful industry engagement.

The analysis identified four distinct pathways through which universities engage industry: scientific collaboration, industry-sponsored clinical research, small-business partnerships, and entrepreneurial training. On the first two pathways, the expected hierarchy holds, and the highest-ranked universities lead. Top-decile institutions publish papers with industry collaborators at rates more than twice those of bottom-decile universities, with 8.9 percent of publications at top-decile schools involving industry co-authors compared with 3.5 percent at bottom-decile institutions. Leading universities also attract higher levels of industry participation in clinical trials, with industry-sponsored trials accounting for 24.5 percent of trial activity among top-decile universities versus 19.0 percent among bottom-decile institutions. Notably, that clinical trial gap is far narrower than the co-authorship gap, an early indication that industry engagement is not confined to elite institutions.

On the other two pathways, the conventional ranking story reverses entirely. Through the federal Small Business Technology Transfer program, bottom-decile universities earn STTR awards at a rate of 0.82 per $10 million in research funding, against 0.18 for top-decile institutions, a rate more than four times higher. Data from the National Science Foundation’s Innovation Corps program show a similar inversion: while top-ranked universities are more likely to participate in I-Corps overall, lower-ranked universities earn I-Corps awards at more than five times the rate per research dollar, 0.83 versus 0.15 per $10 million. In practical terms, institutions outside the traditional research elite are building commercialization engines through entrepreneurship and small-business collaboration at a pace that their better-funded peers have not matched.

The scale of the divergence is striking when expressed in absolute terms. Bottom-decile institutions form small-business research partnerships at more than four times the rate of top-decile universities per research dollar, and they earn federal entrepreneurship-training awards at more than five times the rate. Perhaps the most dramatic individual example is the University of Texas Health Science Center at Tyler, ranked 184th overall on the Cure Innovation Index. That institution runs nearly nine out of every 10 of its clinical trials with an industry partner, about three and a half times the rate of the top-ranked decile, working across 13 pharmaceutical and biotech partners with a portfolio concentrated in oncology and hematology. Its performance illustrates the central finding of the analysis: meaningful industry engagement can emerge far beyond the universities that traditionally dominate discussions about research excellence and innovation.

Standout performers appear at every tier of the rankings, and the analysis suggests they follow recognizably different models. The University of California, San Diego, ranked seventh, and the University of Pennsylvania, ranked third, exemplify what might be called the elite research partnership model, combining strong overall performance with deep industry engagement through scientific collaboration and industry-sponsored clinical research. UC San Diego recorded industry co-authorship at 11.1 percent of publications and industry sponsorship on 30.2 percent of its 543 assessed trials, while Penn posted 8.8 percent co-authorship and 23.3 percent industry sponsorship across 754 trials. Both institutions demonstrate that the traditional strengths of flagship research universities translate directly into industry appeal for large-scale scientific and clinical collaboration.

A different model emerges among mid-ranked institutions that have invested heavily in entrepreneurial infrastructure. The University of Connecticut, ranked 99th, and the University of Georgia, ranked 118th, outperform many higher-ranked peers in industry-facing entrepreneurial activity and small-business partnerships. UConn earned STTR awards at a rate of 0.64 per $10 million in research funding and recorded industry sponsorship on 24.7 percent of its 81 assessed trials, while Georgia posted an STTR rate of 0.66 per $10 million. Both figures substantially exceed the rates achieved by top-decile universities, showing that commercialization strength is not limited to the highest-ranked research universities and that deliberate investment in technology transfer and startup support can yield measurable industry engagement even without an elite research portfolio.

The implications run in both directions. For pharmaceutical, biotech, and other industry organizations seeking university partners, the analysis suggests that institutional reputation alone is a poor proxy for fit. Seema Kumar, CEO of Cure, the healthcare innovation ecosystem headquartered in New York City, noted that a company seeking large-scale clinical research may find its best fit at a university with an affiliated medical center, while one looking for entrepreneurial partnerships may find stronger opportunities at an institution with deep startup and technology-transfer support. In other words, the optimal partner depends on the objective, and the data now exist to make that match systematically rather than by reputation.

For universities themselves, Kumar emphasized that the analysis offers an equally important lesson: there is no single path to successful industry engagement. Institutions can build meaningful partnerships by leaning into their particular strengths rather than trying to replicate a single model borrowed from the most famous research universities. A specialized health science center in East Texas and a flagship land-grant university in Georgia are demonstrating that focused strategies, whether concentrated clinical trial operations in oncology or aggressive pursuit of small-business technology transfer awards, can generate industry revenue and research opportunities that partially insulate institutions from federal funding volatility. What surprised the Cure team, Kumar said, is that some universities excel in clinical research and scientific collaboration while others build powerful commercialization engines through entrepreneurship, and in some cases institutions outside the traditional elite may have lessons to teach the rest of the sector.

The analytical foundation behind these findings is itself notable. The Cure Innovation Index, launched in April 2026, evaluates 25 indicators across three core domains: Research Capabilities, Entrepreneurial Readiness, and Market Translation. It ranks the top 303 academic institutions, comprising 243 universities and 60 institutes and centers, from a field of more than 6,000 nationwide, and provides peer-benchmarked comparisons along with customized improvement recommendations. The methodology integrates validated data from more than a dozen federal and commercial databases, including the National Science Foundation’s Higher Education Research and Development Survey and Dimensions, an interlinked research information system provided by Digital Science. By normalizing partnership metrics against institutional research funding, the index reveals patterns of engagement that raw dollar figures would obscure, and it is precisely those normalized comparisons that expose the unexpected strength of lower-ranked institutions. As federal appropriations remain unresolved and universities confront the prospect of sustained funding pressure, the analysis suggests that the most resilient institutions of the coming decade may be those that treat industry not as a supplementary revenue stream but as a structural partner, and that discover, as the data show, that the door to such partnership is open far wider than the rankings imply.

Subject of Research: University-industry research partnerships as an alternative funding pathway for U.S. biomedical research institutions

Article Title: Industry partnerships offer new opportunities for universities amid federal funding pressures

Article References: Industry partnerships offer new opportunities for universities amid federal funding pressures. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: university-industry partnerships, biomedical research funding, Cure Innovation Index, NIH budget cuts, clinical trials, STTR program, I-Corps, technology transfer, translational science, entrepreneurship, research universities, pharmaceutical industry